en · de · es
sermorelin-notes.peptides1126.com › News › Bremelanotide Background And Receptor Pharmacology — Beginner to Advanced

Bremelanotide Background And Receptor Pharmacology — Beginner to Advanced

By Editorial Desk · published 2026-03-14 · last reviewed 2026-04-24 · News

PT-141 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Bremelanotide Background and Receptor Pharmacology

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Storage Stability and Analytical Methods

Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.

Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.

Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.

Pt-141 at a glance

PropertyValueNotes
Research codePT-141Used in early literature before the generic name became common
Generic nameBremelanotideInternational nonproprietary name
Peptide classCyclic heptapeptideSeven residues joined by a lactam bridge
Primary receptorMC4RLower affinity reported at MC1R, MC3R and MC5R
Route studied clinicallySubcutaneous injectionIntranasal route was abandoned after pressor effects

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Related pages on this site

Receptor Pharmacology and Study Measures

Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.

Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.

After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.

Bremelanotide Naming and Background

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.

Reference notes

== Taxonomy == The plant is part of the family Lamiaceae. A later described species, named S. sieboldii, in dedication to the German-Dutch botanist and japanologist Philipp Franz von Siebold, is considered to be a synonym.

for an n electron process. Focusing on current, reversible couples are characterized by ipa/ipc = 1. When a reversible peak is observed, thermodynamic information in the form of a half cell potential E01/2 can be determined. When waves are semi-reversible (ipa/ipc is close but not equal to 1), it may be possible to determine even more specific information (see electrochemical reaction mechanism). The current maxima for oxidation and reduction itself depend on the scan rate, see the figure.

In many ways, early Knoxville was a typical rowdy late-18th century frontier village. A detached group of Cherokee, known as the Chickamaugas, refused to recognize the Holston treaty, and remained a constant threat. In September 1793, a large force of Chickamaugas and Creeks marched on Knoxville, and massacred the inhabitants of Cavet's Station (near modern Bearden) before dispersing. Outlaws roamed the city's periphery, among them the Harpe Brothers, who murdered at least one settler in 1797 before fleeing to Kentucky. Abishai Thomas, an associate of Blount who visited Knoxville in 1794, noted that the city was full of taverns and tippling houses, no churches, and that the blockhouse's jail was overcrowded with criminals. In 1795, James White set aside more land for the growing city, allowing it to expand northward to modern Clinch Avenue and westward to modern Henley Street. A census that year showed that Tennessee had a large enough population to apply for statehood. In January 1796, delegates from across Tennessee, including Blount, Sevier, and Andrew Jackson, convened in Knoxville to draw up a constitution for the new state, which was admitted to the Union on June 1, 1796. Knoxville was chosen as the initial capital of the state.

In 1676, Anton van Leeuwenhoek observed bacteria and other microorganisms, using a single-lens microscope of his own design. In 1796, Edward Jenner developed a method using cowpox to successfully immunize a child against smallpox. The same principles are used for developing vaccines today. Following on from this, in 1857 Louis Pasteur also designed vaccines against several diseases such as anthrax, fowl cholera and rabies as well as pasteurization for food preservation. In 1867 Joseph Lister is considered to be the father of antiseptic surgery. By sterilizing the instruments with diluted carbolic acid and using it to clean wounds, post-operative infections were reduced, making surgery safer for patients. In the years between 1876 and 1884 Robert Koch provided much insight into infectious diseases. He was one of the first scientists to focus on the isolation of bacteria in pure culture. This gave rise to the germ theory, a certain microorganism being responsible for a certain disease. He developed a series of criteria around this that have become known as the Koch's postulates. A major milestone in medical microbiology is the Gram stain. In 1884 Hans Christian Gram developed the method of staining bacteria to make them more visible and differentiated under a microscope. This technique is widely used today. In 1910 Paul Ehrlich tested multiple combinations of arsenic based chemicals on infected rabbits with syphilis. Ehrlich then found that arsphenamine was found effective against syphilis spirochetes. The arsphenamines was then made available in 1910, known as Salvarsan.

== Medical uses == Brief reactive psychosis and hypochondriasis-senestopathic syndrome Vegetative dysfunction and vegetative lability Alcohol withdrawal syndrome Temporal lobe epilepsy and myoclonic epilepsy (used only occasionally as better options exist) Hyperkinesia and tics Muscle spasticity Usually, a course of treatment with phenazepam should not normally exceed 2 weeks (in some cases therapy may be prolonged for up to 2 months) due to the risk of drug abuse and dependence. To prevent withdrawal syndrome, it is necessary to reduce the dose gradually.

Sources: en.wikipedia.org

Reference notes

== History == Conjugated estriol, an extract of the urine of pregnant women and sold under the brand names Progynon and Emmenin in the 1930s, was the predecessor of Premarin. Both of these products contained conjugated estrogens similarly to Premarin, but the estrogens were human estrogens as opposed to equine estrogens and the composition differed. The major active ingredient in Progynon and Emmenin was estriol glucuronide. Estrone sulfate was first isolated from the urine of pregnant mares in the late 1930s by researchers in the Department of Biochemistry at University of Toronto. Premarin was first introduced in 1941 by Wyeth Ayerst as a treatment for hot flashes and other symptoms of menopause; at that time, Wyeth Ayerst only had to prove its safety, and not its efficacy. In response to the 1962 Kefauver Harris Amendment the FDA had its efficacy reviewed, and in 1972 found it effective for menopausal symptoms and probably effective for osteoporosis. The review also determined that two estrogens – estrone sulfate and equilin sulfate – were primarily responsible for the activity of Premarin, and it laid the groundwork for Abbreviated New Drug Application (ANDA) submissions of generic versions. In 1984 an NIH consensus panel found that estrogens were effective for preventing osteoporosis and 1986 the FDA announced in the Federal Register that Premarin was effective for preventing osteoporosis. This announcement led to a rapid growth in sales, and interest from generic manufacturers to introduce generic versions.

===== Scotland ===== There are four NHS Scotland Gender Identity Clinics providing services to adults and a separate service for younger people. The National Gender Identity Clinical Network for Scotland reported in 2021 that some patients had waited in excess of two years from referral for their first appointment. Minister for Public Health Maree Todd has stated that the Scottish Government wants to reduce "unacceptable waits to access gender identity services". Research has indicated patient dissatisfaction with long wait times. However, overall experience of treatment outcomes was largely positive, particularly for hormone therapy and surgery.

=== Early life === Endre Mester was born on November 20, 1903, in Budapest, Hungary. He studied medicine at University of Pécs, Hungary until 1927. He then taught surgery at the Pazmany Peter University in Budapest, while working with Dr. Lajos Adam. He was certified both in surgery and in radiology.

For morphological data, recent simulation studies suggest that parsimony may be less accurate than trees built using Bayesian approaches, potentially due to overprecision, although this has been disputed. Studies using novel simulation methods have demonstrated that differences between inference methods result from the search strategy and consensus method employed, rather than the optimization used. As in maximum parsimony, maximum likelihood will evaluate alternative trees. However it considers the probability of each tree explaining the given data based on a model of evolution. In this case, the tree with the highest probability of explaining the data is chosen over the other ones. In other words, it compares how different trees predict the observed data. The introduction of a model of evolution in ML analyses presents an advantage over MP as the probability of nucleotide substitutions and rates of these substitutions are taken into account, explaining the phylogenetic relationships of taxa in a more realistic way. An important consideration of this method is the branch length, which parsimony ignores, with changes being more likely to happen along long branches than short ones. This approach might eliminate long branch attraction and explain the greater consistency of ML over MP. Although considered by many to be the best approach to inferring phylogenies from a theoretical point of view, ML is computationally intensive and it is almost impossible to explore all trees as there are too many.

He also stated that the novel "historicizes and theorizes animal life and death," and that it demonstrates the ways that symbolism and materiality of meat are "co-opted within patriarchal political structures," putting it in the same space as theorists like Carol J. Adams, Donna J. Haraway, Laura Wright, and Cary Wolfe, and writers such as J. M. Coetzee. In 1997, S. Reneé Wheeler wrote in the Vegetarian Journal, saying that "finding books with vegetarian themes" is important for helping children "feel legitimate in being vegetarian." In 2004, writer J. M. Coetzee argued that since the "mode of consciousness of nonhuman species is quite different from human consciousness," it is hard for writers to realize this for animals, with a "temptation to project upon them feelings and thoughts that may belong only to our own human mind and heart," and stated that reviewers have ignored the presence of animals in his books. He also stated that animals are present in his "fiction either not at all or in a merely subsidiary role" because they occupy "a subsidiary place in our lives" and argued that it is not "possible to write about the inner lives of animals in any complex way." In 2014, The New Yorker published a short story by Jonathan Lethem titled "Pending Vegan" which follows "one family, a husband and wife and their four-year-old twin daughters" on a trip to SeaWorld in San Diego, California.

Sources: en.wikipedia.org

Frequently asked questions

What does the PT-141 code refer to?

The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.

Which receptor is considered the principal target?

MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.

How does it relate to melanotan II?

Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.

How is purity typically reported for this peptide?

Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.

Network